Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

被引：0
|
作者：
Takeru Shiroiwa
Takashi Fukuda
Kojiro Shimozuma
Mitsuko Mouri
Yasuhiro Hagiwara
Takuya Kawahara
Shozo Ohsumi
Yasuo Hozumi
Yoshiaki Sagara
Yasuo Ohashi
Hirofumi Mukai
机构：
[1] Department of Health and Welfare Services,Department of Biomedical Sciences, College of Life Sciences
[2] National Institute of Public Health,Department of Biostatistics, School of Public Health
[3] Ritsumeikan University,Biostatistics Division, Clinical Research Support Center
[4] Kanagawa Academy of Science and Technology (KAST),Department of Breast and Endocrine Surgery
[5] The University of Tokyo,Department of Integrated Science and Engineering
[6] The University of Tokyo Hospital,undefined
[7] Department of Breast Oncology,undefined
[8] National Hospital Organization Shikoku Cancer Center,undefined
[9] University of Tsukuba Hospital,undefined
[10] Department of Breast Surgery,undefined
[11] Ibaraki Prefectural Central Hospital,undefined
[12] Breast Surgery Department,undefined
[13] Social Medical Corporation Hakuaikai Sagara Hospital,undefined
[14] Chuo University,undefined
[15] Division of Breast and Medical Oncology,undefined
[16] National Cancer Center Hospital East,undefined
来源：
BMC Cancer | / 17卷
关键词：
Cost-effectiveness analysis; Quality-adjusted life years; Breast neoplasms; Randomized controlled trial; S-1; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer.
    Chernozemsky, I
    Kalinov, K.
    Tzekov, H.
    Racheva, M.
    Hristova, S.
    Tomova, A.
    Koynova, T.
    Taskova, V
    Boideva, L.
    Eniu, A.
    Krasteva, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S119 - S119
  • [32] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [33] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
    Dai, Yu-Hong
    Yu, Xiong-Jie
    Xu, Hui-Ting
    Zhuang, Liang
    Zhang, Ming-Sheng
    Zou, Yan-Mei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xiang-Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [34] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial
    Nabholtz, JM
    Falkson, C
    Campos, D
    Szanto, J
    Martin, M
    Chan, S
    Pienkowski, T
    Zaluski, J
    Pinter, T
    Krzakowski, M
    Vorobiof, D
    Leonard, R
    Kennedy, I
    Azli, N
    Murawsky, M
    Riva, A
    Pouillart, P
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 968 - 975
  • [35] Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer
    Higuchi, Katsuhiko
    Koizumi, Wasaburo
    Yamada, Yasuhide
    Nishikawa, Kazuhiro
    Gotoh, Masahiro
    Fuse, Nozomu
    Sugimoto, Naotoshi
    Nishina, Tomohiro
    Amagai, Kenji
    Chin, Keisho
    Niwa, Yasumasa
    Negoro, Yuji
    Imamura, Hiroshi
    Tsuda, Masahiro
    Yasui, Hirotumi
    Fujii, Hirofumi
    Yamaguchi, Kensei
    Yasui, Hisateru
    Hamada, Chikuma
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
    Jassem, J
    Pienkowski, T
    Pluzanska, A
    Jelic, S
    Gorbunova, V
    Mrsic-Krmpotic, Z
    Berzins, J
    Nagykalnai, T
    Wigler, N
    Renard, J
    Munier, S
    Weil, C
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1707 - 1715
  • [37] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Lee, Keun-Wook
    Chung, Ik-Joo
    Ryu, Min-Hee
    Park, Young Iee
    Nam, Byung-Ho
    Oh, Ho-Suk
    Lee, Kyung Hee
    Han, Hye Sook
    Seo, Bong-Gun
    Jo, Jae-Cheol
    Lee, Hyo Rak
    Kim, Jin Won
    Park, Sook Ryun
    Cho, Sang Hee
    Kang, Yoon-Koo
    GASTRIC CANCER, 2021, 24 (01) : 156 - 167
  • [38] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Keun-Wook Lee
    Ik-Joo Chung
    Min-Hee Ryu
    Young Iee Park
    Byung-Ho Nam
    Ho-Suk Oh
    Kyung Hee Lee
    Hye Sook Han
    Bong-Gun Seo
    Jae-Cheol Jo
    Hyo Rak Lee
    Jin Won Kim
    Sook Ryun Park
    Sang Hee Cho
    Yoon-Koo Kang
    Gastric Cancer, 2021, 24 : 156 - 167
  • [39] Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
    Elomaa, I
    Joensuu, H
    Blomqvist, C
    ANNALS OF ONCOLOGY, 2003, 14 (05) : 699 - 703
  • [40] Multicenter phase II trial of S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable colorectal cancer
    Shin, S.
    Park, Y.
    Kim, T.
    Oh, D.
    Shim, B.
    Lee, K.
    Lee, M.
    Kim, Y.
    Kim, Y.
    Ahn, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345